(-)-Vinigrol

CAS: 111025-83-3

Ref. 3D-FV176651

Produktinformation

• Name: (-)-Vinigrol
• Synonyme: (1R,4S,4aS,5S,8R,8aS,9R,12R)-4,4a,5,6,7,8-Hexahydro-3-(hydroxymethyl)-8,9-dimethyl-12-(1-methylethyl)-1,5-butanonaphthalene-4,8a(1H)-diol, (1R,4S,4aS,5S,8R,8aS,9S,12S)-3-(hydroxymethyl)-8,12-dimethyl-9-(1-methylethyl)-4,4a,5,6,7,8-hexahydro-1,5-butanonaphthalene-4,8a(1H)-diol, 1,5-Butanonaphthalene-4,8a(1H)-diol, 4,4a,5,6,7,8-hexahydro-3-(hydroxymethyl)-8,9-dimethyl-12-(1-methylethyl)-, (1R,4S,4aS,5S,8R,8aS,9R,12R)-, 1,5-Butanonaphthalene-4,8a(1H)-diol, 4,4a,5,6,7,8-hexahydro-8,9-dimethyl-3-(hydroxymethyl)-12-(1-methylethyl)-, (1R-(1-alpha,4-beta,4a-beta,5-alpha,8-beta,8a-beta,9S*,12S*))-, Antibiotic FR 900478, Brn 5063688

Beschreibung

(-)-Vinigrol is a synthetic analogue of the cardiac glycoside ouabain. It has been shown to have antihypertensive activity, which may be due to its ability to inhibit angiotensin-converting enzyme. (-)-Vinigrol has also been shown to have immunosuppressive and anti-inflammatory properties, as well as being used in the treatment of autoimmune diseases and degenerative diseases. This drug is administered orally, with an elimination half-life of about 9 hours. The therapeutic dose for congestive heart disease is 100 mg/day, while for inflammatory diseases it is up to 400 mg/day.

• Marke: Biosynth

Chemische Eigenschaften

• Reinheit: Min. 95%